Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma

Clinical Cancer Research

Volumn 21, Issue 21, 2015, Pages 4935-4946

  Agelopoulos, Konstantin ^a   Richter, Günther H S ^b,c   Schmidt, Eva ^a   Dirksen, Uta ^a   Von Heyking, Kristina ^b,c   Moser, Benjamin ^a   Klein, Hans Ulrich ^d   Kontny, Udo ^e   Dugas, Martin ^d   Poos, Kathrin ^a   Korsching, Eberhard ^a   Buch, Thorsten ^f,g   Weckesser, Matthias ^d   Schulze, Isabell ^a,h   Besoke, Regina ^d   Witten, Anika ^d   Stoll, Monika ^d   Köhler, Gabriele ⁱ   Hartmann, Wolfgang ^d   Wardelmann, Eva ^d   Rossig, Claudia ^a   Baumhoer, Daniel ^j   Jürgens, Heribert ^a   Burdach, Stefan ^b,c   Berdel, Wolfgang E ^a   Müller Tidow, Carsten ^a,h   more..

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

ⁱ KLINIKUM FULDA   (Germany)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUORODEOXYGLUCOSE F 18; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKRD30A GENE; ARTICLE; CANCER RECURRENCE; CCDC19 GENE; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; EWING SARCOMA; EWING SARCOMA CELL LINE; EXOME; FEMALE; FGFR1 GENE; GENE; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENE SEQUENCE; HUMAN; KIAA0319 GENE; KIAA1522 GENE; LAMB4 GENE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RNA INTERFERENCE; SCHOOL CHILD; SEQUENCE ANALYSIS; SLFN11 GENE; SOMATIC MUTATION; STAG2 GENE; TP53 GENE; UNC80 GENE; ZNF98 GENE; ADOLESCENT; ANIMAL; CANCER STAGING; COPY NUMBER VARIATION; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; KNOCKOUT MOUSE; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; CELL LINE, TUMOR; CHILD; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MICE, KNOCKOUT; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SARCOMA, EWING; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84947253949     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2744     Document Type: Article

References (45)

1. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009;106:5324-9.
2. von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, Cooper A, et al. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One 2011;6:e19305.
3. Ewing J. Diffuse endothelioma of bone. Proc N Y Path Soc 1921;7:17-24.
4. Schmidt D, Harms D, Burdach S. Malignant peripheral neuroectodermal tumours of childhood and adolescence. Virchows Arch A Pathol Anat Histopathol 1985;406:351-65.
5. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64:8213-21.
6. Hauer K, Calzada-Wack J, Steiger K, Grunewald TG, Baumhoer D, Plehm S, et al. DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. Cancer Res 2013;73:967-77.
7. Tanaka M, Yamazaki Y, Kanno Y, Igarashi K, Aisaki K, Kanno J, et al. Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. J Clin Invest 2014;124:3061-74.
8. Aurias A, Rimbaut C, Buffe D, Zucker JM, Mazabraud A. Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. Cancer Genet Cytogenet 1984;12:21-5.
9. Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir GM. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet Cytogenet 1984;12:1-19.
10. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, Israel MA. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 1984;311:584-5.
11. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
12. Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 2012;7:145-59.
13. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005;23:548-58.
14. Jahromi MS, Jones KB, Schiffman JD. Copy number alterations and methylation in Ewing's Sarcoma. Sarcoma 2011;2011:362173.
15. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 2012;31:1287-98.
16. Postel-Vinay S, Veron AS, Tirode F, Pierron G, Reynaud S, Kovar H, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 2012;44:323-7.
17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. ell 2011;144:646-74.
18. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
19. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
20. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.
21. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
22. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011;331:435-9.
23. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012;122:2983-8.
24. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012;44:251-3.
25. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012;481:329-34.
26. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13.
27. Stahl M, Ranft A, Paulussen M, Bolling T, Vieth V, Bielack S, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011;57:549-53.
28. Rasper M, Jabar S, Ranft A, Jurgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer 2014;61:1382-6.
29. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012;149:979-93.
30. Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell 2012;46:424-35.
31. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011;333:1039-43.
32. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 2014;10:e1004475.
33. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing Sarcoma. Cancer Discov 2014;4:1326-41.
34. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014;4:1342-53.
35. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Marquez M, Vazquez M, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013;45:1464-9.
36. Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013;45:927-32.
37. Lew ED, Furdui CM, Anderson KS, Schlessinger J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal 2009;2:ra6.
38. Lynn M, Wang Y, Slater J, Shah N, Conroy J, Ennis S, et al. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma. Diagn Mol Pathol 2013;22:76-84.
39. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012;11:690-9.
40. Kovar H. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opin Ther Targets 2014;18:1315-28.
41. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150:264-78.
42. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res 2014;20:3299-309.
43. Malchers F, Dietlein F, Schottle J, Lu X, Nogova L, Albus K, et al. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov 2014;4:246-57.
44. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 2014;40:770-80.
45. Greenblatt SM, Nimer SD. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia 2014;28:1396-406.